Investor Presentaiton

Blazing a trail for a true liquid MRD test 1 2 3 INVESTOR 20 Revolutionary Smart Liquid. Biopsy technology achieving high sensitivity with >98% clinical specificity Clinical validation on thousands of patients across dozens of tumor types to secure reimbursement Leverage existing market-leading oncology commercial infrastructure to scale with speed GUARDANT™ DAY 23 63

View entire presentation